Improving Patient Safety In Radiation Therapy With The Watchdog Real-time Treatment Delivery Verification System
Funder
National Health and Medical Research Council
Funding Amount
$593,742.00
Summary
Radiation therapy is a highly effective cancer treatment with extremely high doses delivered using very complex treatment machines. Unfortunately errors have occurred resulting in cases of patient death and mistreatment. We have developed a novel method to assess the treatment delivery in real-time to prevent errors. The method uses imaging devices that are already present on the treatment machine meaning that this method could have a major impact on patient safety in modern radiation therapy.
Biofocussed Prostate Cancer RadioTherapy (BiRT): A Personalised Approach To Delivering The Right Dose To The Right Place
Funder
National Health and Medical Research Council
Funding Amount
$753,565.00
Summary
We propose a new approach to treating prostate cancer with radiotherapy to move from the standard whole prostate treatment to a personalised treatment that varies radiation intensity throughout the prostate. We will mathematically combine features that influence radiotherapy effect from advanced imaging, clinical and biopsy information. This model will map out the radiotherapy dose required at each part of the prostate, to maximise killing of the cancer whilst minimising harm to normal tissue
Optimising Radiation Therapy Delivery For Cancer Patients Using Daily Image Guidance To Maximize Cure And Reduce Normal Tissue Side Effects
Funder
National Health and Medical Research Council
Funding Amount
$510,968.00
Summary
When using radiotherapy to kill tumours, the radiation beams need to be targeted at the tumour, plus a margin of error around it to ensure that it receives sufficient dose despite uncertainties in its exact location relative to reference points used for beam alignment. Advanced statistical modelling techniques applied to data collected from patients will be used to determine the optimal margin width for individual patients to maximise cancer cure while minimising normal tissue side effects.
The Role Of Nuclear Architecture In The DNA Damage Response
Funder
National Health and Medical Research Council
Funding Amount
$561,966.00
Summary
The goal of the proposed research is to understand how dynamic changes to the chromatin genome packaging network, interact with the DNA damage response and gene expression machinery, to repair damaged DNA and the impact this has on cancer biology. To do so we are combining cutting edge molecular biology techniques with innovative novel microscopy methods developed by our research team, that far exceed the spatiotemporal resolution currently used to study chromatin biology.
A Randomised Controlled Trial Of Low-dose Ketamine In Youth With Severe Depression And Elevated Suicide Risk
Funder
National Health and Medical Research Council
Funding Amount
$2,232,757.00
Summary
Recent research has shown that a single injection of low-dose ketamine has powerful, though short-lived, antidepressant effects. Effective treatments are urgently needed for young people with severe depression. This will be the first controlled study to test whether repeated doses of ketamine, given over 4 weeks, is effective for young patients.
PARP And PI3K Inhibition In Pancreatic Cancer: Intravital Insights And ‘fine-tune’ Priming Using AKT And Single/double-strand DNA Break Biosensor Mice.
Funder
National Health and Medical Research Council
Funding Amount
$760,505.00
Summary
Inefficient drug response in solid tumour tissue is often a limiting factor in the clinical effectiveness of cancer therapies. Using cutting-edge imaging technology and 3D models that mimic the disease, we can map areas of poor drug response within distinct regions of tumours with chemotherapy. Here, we will shift factors limiting efficient drug targeting in these areas to improve the encouraging anti-cancer profile of PI3K and DNA repair inhibitors in pancreatic cancer.
The Burden Of Late Preterm Birth On Brain Development And 2 Year Outcomes – A Prospective, Longitudinal Cohort Study
Funder
National Health and Medical Research Council
Funding Amount
$838,690.00
Summary
80% of preterm babies are born from 32-36 weeks’ gestation, and are late preterm (LPT). LPT children have more learning problems, but why this occurs is unknown. This study aims to understand the effect of LPT birth on brain development. We will do brain scans at term and assess development at 2 years of age of 200 LPT and 200 full-term children. We expect LPT babies will have subtle alterations in brain development compared with term controls which will be associated with delayed development.
The primary aim of this grants to determine how HIV spreads through our immune system. The above knowledge will determine key Achille’s Heel moments in the HIV life cycle and thus lead to better therapeutic HIV treatments/prevention.
Therapeutic Targeting Of Cell Cycle Checkpoint Aberrations In Pancreatic Cancer: Personalised Medicine In Action
Funder
National Health and Medical Research Council
Funding Amount
$634,354.00
Summary
Less than 5% of people with pancreatic cancer (PC) survive 5 years, and the odds of patients beating this disease have remained unchanged for 50 years. Consequently, there is an urgent need to develop novel treatment approaches for this highly aggressive cancer. Our study aims to define novel therapeutic strategies for PC utilising specific anti-proliferative therapies and a personalised “companion biomarker” directed strategy.